Clustered regularly interspaced short palindromic repeat (CRISPR/Cas) proteins can be designed to bind specified DNA and RNA sequences and hold great promise for the accurate detection of nucleic acids for diagnostics. We integrated commercially available reagents into a CRISPR/Cas9-based lateral flow assay that can detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences with single-base specificity. This approach requires minimal equipment and represents a simplified platform for field-based deployment. We also developed a rapid, multiplex fluorescence CRISPR/Cas9 nuclease cleavage assay capable of detecting and differentiating SARS-CoV-2, influenza A and B, and respiratory syncytial virus in a single reaction. Our findings provide proof-of-principle for CRISPR/Cas9 point-of-care diagnosis as well as a scalable fluorescent platform for identifying respiratory viral pathogens with overlapping symptomology.
【저자키워드】 lateral flow assay, CRISPR/Cas9, SARS-Co-V2, 【초록키워드】 SARS-CoV-2, coronavirus, equipment, Diagnosis, influenza A, diagnostics, lateral flow, Protein, point-of-care, nucleic acid, specificity, pathogen, respiratory syncytial virus, cleavage, multiplex, platform, overlapping, acute respiratory syndrome, sequence, fluorescent, reagent, DNA and RNA, approach, respiratory viral, detect, 【제목키워드】 Fluorescence, Flow, Lateral,